Company profile
Sareum Limited is a UK company with status active founded in 2003 based in East of England.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQzMTg1MzA1MWFkaXF6a2N4
Published 12 Aug 2024 13:01
Company registered at Companies House
1 Dec 2020 to 31 May 2021
Sareum is developing SDC-1801, a small-molecule inhibitor of kinases TYK2 and JAK1, as a potential therapeutic for a wide range of inflammatory diseases such as psoriasis, lupus and Crohn's disease. Cells signal to each other using cytokines, and SDC-1801 works by blocking specific cytokine signalling pathways, leading to reduced inflammation. Covid-19 is...
1 Aug 2015 to 31 Jul 2016
The enzyme TYK2 has been shown to be a key therapeutic target in a rare type of leukaemia, T-ALL, which predominantly affects young adults. Sareum has discovered a novel series of selective inhibitors of TYK2, and have shown that they can prevent T-ALL cells from proliferating by causing programmed cell death. The aim of this feasibility study is to asses...
1 Jun 2013 to 30 Apr 2014
The enzyme Fatty Acid Synthase (FASN) has been shown to be a key therapeutic target in cancer. Most normal cells acquire fatty acids from diet, so do not require or express FASN. By contrast, many types of cancer cell express high levels of FASN, and this expression is associated with poor patient prognosis. Sareum has discovered a novel series of inhibit...
